First developed for cancer immunotherapy, CARs demonstrated their feasibility in early pre-clinical studies in which CD4+FOXP3+ Treg specificity was redirected against antigen relevant to autoimmunity (36, 37). This evidence concerns the gene FOXP3 and Autoimmunity.